- Abstract Number: 098
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
- Abstract Number: 177
Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
- Abstract Number: 009
Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
- Abstract Number: 074
Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
- Abstract Number: 121
Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis
- Abstract Number: 113
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
- Abstract Number: 134
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
- Abstract Number: 193
Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
- Abstract Number: 168
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
- Abstract Number: 031
Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
- Abstract Number: 010
Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
2020 Pediatric Rheumatology Symposium
April 29-May 2, 2020
The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.